Related by context. All words. (Click for frequent words.) 71 ARIXTRA 65 nonfatal MI 65 Peginterferon Alfa 2a 65 ATACAND 65 eplerenone 64 GP IIb IIIa inhibitors 64 ximelagatran 64 unfractionated heparin UFH 64 invasive aspergillosis 64 refractory ischemia 64 idraparinux 64 salmeterol fluticasone 64 XIENCE V PROMUS Stent 63 thromboembolism 63 #.#mg/dL 63 recurrent venous thromboembolism 63 cardiovascular hospitalization 63 ARCOXIA 63 lopinavir r arm 63 MULTAQ 63 adjunctive placebo 63 mycophenolate mofetil 63 benazepril 63 thromboembolic events 63 clodronate 62 p = NS 62 HYZAAR 62 salmeterol inhalation powder 62 composite endpoint 62 venous thromboembolic events 62 plus GP IIb 62 ischemic complications 62 events MACE 62 candesartan cilexetil 62 COZAAR 62 colesevelam HCl 62 atorvastatin #mg 62 BYSTOLIC 62 reinfarction 62 NOLVADEX 62 aspirin clopidogrel 62 Hazard Ratio 62 Nebulized 62 arterial thromboembolic events 62 mcg QD 62 thromboembolic complications 62 5-FU/LV 62 posaconazole 62 Ranolazine 61 fatal myocardial infarction 61 Insulin Glargine 61 endometrial hyperplasia 61 oxycodone CR 61 #.#/#.# mmHg [001] 61 angiotensin converting enzyme inhibitors 61 #mg BID [001] 61 nonfatal myocardial infarction 61 nonfatal stroke 61 REMICADE monotherapy 61 mg BID dose 61 rFVIIa 61 BENICAR HCT 61 abacavir lamivudine 61 symptomatic VTE 61 ACTEMRA TM 61 TAXUS p value 61 valsartan 61 Interferon beta 1b 61 ertapenem 61 PREZISTA r arm 61 ALT elevation 61 binary restenosis 61 perioperative mortality 61 #mg BID [003] 60 cardiovascular hospitalizations 60 morphometric vertebral fractures 60 HMG CoA reductase inhibitors 60 oral allopurinol 60 metastatic GIST 60 severe exacerbations 60 acarbose 60 ULORIC 60 GP IIb IIIa inhibitor 60 systemic corticosteroid 60 lanthanum carbonate 60 Bivalirudin 60 thrombotic events 60 systemic embolism 60 atherothrombotic events 60 DULERA 60 PRADAXA 60 macrovascular events 60 STRIDE PD 60 non valvular atrial 60 nonfatal myocardial infarction MI 60 nadroparin 60 adjunctive ABILIFY 60 fluticasone salmeterol 60 Mg Uk 60 NPH insulin 60 plus dexamethasone 60 FOLFIRI 60 del 5q MDS 60 Acetate Rectal Suppositories 60 stable angina pectoris 60 LMWH 60 Renal dysfunction 60 glimepiride 60 antiplatelet agent 60 Abciximab 60 recurrent VTE 60 TAXUS Stent 60 severe renal insufficiency 60 CIMZIA ™ 60 invasive candidiasis 60 divalproex sodium 60 Erythropoietic therapies may 59 nicardipine 59 CANCIDAS 59 amoxicillin clavulanate 59 tapentadol ER 59 plus glycoprotein IIb 59 generalized edema 59 achieved ACR# 59 venous thromboembolism VTE 59 Pioglitazone 59 fondaparinux 59 equi analgesic doses 59 IIIa inhibitor 59 antiplatelet drugs 59 Tiotropium 59 β blockers 59 glycated hemoglobin levels 59 Betaferon R 59 NovoLog ® Mix 59 biphasic insulin aspart 59 alteplase 59 macrovascular 59 ischemia driven 59 Ishak fibrosis score 59 myocardial infarction stroke 59 FRAGMIN 59 Restenosis 59 recurrent DVT 59 definite stent thrombosis 59 rizatriptan 59 olmesartan medoxomil hydrochlorothiazide 59 titrated glipizide 59 metformin sulfonylurea 59 LPV r 59 Thrombolysis 59 clopidogrel Plavix 59 neutropenia dehydration dyspnea 59 salmeterol fluticasone propionate 59 salmeterol HFA MDI 59 BENICAR 59 sotalol 59 antiarrhythmic drug 59 Pred Forte 59 cilostazol 59 Valacyclovir 59 levosimendan 59 vildagliptin 59 HBeAg negative patients 59 severe renal impairment 59 NNT = 59 IOP lowering 59 deep venous thromboses 59 Famotidine 59 Crohn Disease Activity 59 AVANDIA 59 febrile neutropenia 59 simvastatin #mg 59 Lantus ® 58 FOLFOX4 58 tolterodine ER 58 ipsilateral stroke 58 Ramipril 58 oral antidiabetic medication 58 bivalirudin 58 ug kg 58 dalteparin 58 tirofiban 58 sirolimus stent 58 ALVESCO 58 angiotensin receptor blockers 58 venous thromboembolisms 58 Mg Usa 58 apolipoprotein B 58 thromboembolic 58 nonvertebral fractures 58 saline placebo 58 TEAEs 58 cardiovascular morbidity 58 ezetimibe simvastatin 58 KOMBIGLYZE XR 58 leukopenia 58 lipid lowering agents 58 aldosterone antagonist 58 periprocedural 58 CIMZIA TM 58 FOLFOX4 alone 58 insulin detemir 58 cyclophosphamide methotrexate 58 HbA 1c levels 58 nephrotoxicity 58 ST Segment Elevation 58 segment binary restenosis 58 chlorthalidone 58 candesartan 58 enoxaparin 58 lispro 58 unfractionated heparin 58 infusional 58 insulin glargine 58 balsalazide 58 lipoprotein Lp 58 Folfox 58 olmesartan 58 symptomatic intracranial 58 thromboembolic disorders 58 Antihypertensive 58 serum aminotransferase levels 58 mcg BID 58 polyp recurrence 58 infliximab monotherapy 58 noninferior 58 pyrexia mucositis sepsis febrile 58 irbesartan 58 NATRECOR ® 58 INEGY 58 Nesiritide 58 mcg linaclotide 58 ACE Inhibitor 58 nitroprusside 58 angiotensin converting enzyme inhibitor 58 PREZISTA r 58 β blocker 58 fluvastatin 58 adalimumab 58 q#h 58 MetroGel R 57 secondary efficacy endpoint 57 Events MACE 57 hypokalemia 57 ARB telmisartan 57 Doxil ® 57 Percutaneous Coronary Intervention 57 Hypotension 57 Hb A1C 57 #mg doses [002] 57 Acute Myocardial Infarction 57 azacitidine 57 aspartate aminotransferase AST 57 stomatitis pharyngitis 57 octreotide LAR 57 Operative mortality 57 resuscitated cardiac arrest 57 colorectal adenoma 57 antiplatelet medications 57 VIRAMUNE 57 μg kg 57 LANTUS R 57 abciximab 57 #.#g/day 57 Montelukast 57 receiving INTRON 57 serum triglycerides 57 NeoRecormon 57 hypercholesterolaemia 57 PROCTOCORT ® Suppository Hydrocortisone 57 besifloxacin ophthalmic suspension 57 uncoated stent 57 oxcarbazepine 57 mg qd 57 GlaxoSmithKline Requip 57 #mg dose [003] 57 primidone 57 certolizumab 57 QTc prolongation 57 HBeAg seroconversion 57 CMV disease 57 CR nPR 57 budesonide pMDI 57 eptifibatide 57 severe neutropenia 57 glulisine 57 flutamide 57 Is Well Tolerated 57 acute coronary syndromes ACS 57 baseline serum creatinine 57 norgestimate 57 contrast induced nephropathy 57 venous thromboembolic disease 57 PRADAXA #mg 57 microgram kg 57 SPIRIVA ® 57 hypomagnesemia 57 upper gastrointestinal bleeding 57 APTIVUS r 57 low dose Iluvien 57 pegylated interferon alfa 2b 57 TAXUS Liberte Long 57 ramipril 57 HBeAg positive patients 57 unresectable HCC 57 Engerix B 57 ß blockers 57 MICARDIS 57 Demonstrated Significant 57 tibolone 57 NYHA Class II 57 recurrent ischemia 57 chemoradiation therapy 57 GnRH agonist 57 μg dose 57 p = .# [001] 57 cerebrovascular events 57 Percutaneous Transluminal Coronary Angioplasty 57 tamsulosin 57 thromboses 57 ACE inhibitor ramipril 57 mcg dose 57 RLAI 57 mRCC 57 aldosterone antagonists 57 #mg/day [001] 57 comparator arm 57 tolvaptan 57 Treated Patients 57 FluCAM arm 57 chlorambucil 56 hepatotoxicity 56 angiographic restenosis 56 hydroxymethyl coenzyme 56 mg TID 56 baseline FEV 56 primary hypercholesterolemia 56 Benazepril 56 thrombosis embolism 56 concomitant medications 56 IIIa inhibitors 56 metformin hydrochloride 56 HF hospitalization 56 Ischemic 56 mcg albinterferon alfa 2b 56 angiotensin II receptor blockers 56 serum phosphorous 56 antiplatelet agents 56 pericardial effusion 56 4mg/kg 56 ivabradine 56 pulmonary exacerbations 56 quetiapine risperidone 56 receiving prophylactic anticoagulation 56 Lantus R 56 recurrent glioblastoma multiforme 56 gout flares 56 leukocyte count 56 rosuvastatin #mg 56 FROVA 56 moderate renal impairment 56 complete cytogenetic response 56 artery reclogging 56 patients undergoing CABG 56 death reinfarction 56 CI #.#-#.# [002] 56 heparin induced thrombocytopenia 56 hepatorenal syndrome 56 NMIBC 56 CsA 56 lumbar spine bone 56 ticagrelor 56 % AST SGOT 56 pooled comparator 56 Elitek 56 CYPHER Stent 56 thromboprophylaxis 56 HMG CoA reductase inhibitor 56 antithrombotic 56 lumbar spine BMD 56 Flu Cy 56 necrotizing pancreatitis 56 -#.# mg dL [001] 56 Topical Cream 56 vecuronium 56 H2 blockers 56 locoregional recurrence 56 myocardial infarction ventricular fibrillation 56 lamotrigine 56 Acute Coronary Syndromes 56 arterial thrombosis 56 #mg/day [002] 56 Lovaza ® 56 TAXUS Express Stent 56 intravitreal injections 56 intravenous bisphosphonates 56 discontinuations due 56 peginterferon alfa 2a 56 EXJADE 56 stroke myocardial infarction 56 ticlopidine 56 serum phosphorus 56 -#.# log# 56 plus aztreonam 56 revascularizations 56 symptomatic intracranial hemorrhage 56 severe oral mucositis 56 atherogenic dyslipidemia 56 indinavir 56 highly emetogenic 56 mcg mL 56 serum potassium 56 neointimal hyperplasia 56 sUA 56 Median PFS 56 SGPT 56 confidence interval #.#-#.# 55 pulmonary embolus 55 thienopyridines 55 NATRECOR R 55 % CI #.#-#.# [004] 55 Thal Dex 55 mg BID 55 mg QD 55 log# copies mL 55 Lactic acidosis 55 prespecified secondary 55 PASI scores 55 PAOD 55 Castration Resistant Prostate Cancer 55 mL/min/#.# m 2 55 intravenous bolus 55 everolimus eluting stents 55 lopinavir r 55 LV dysfunction 55 corticosteroid dose 55 % CI #.#-#.# [006] 55 Fluticasone Propionate 55 myocardial infarction MI 55 metastatic malignant 55 XIENCE V vs. 55 tacrolimus capsules 55 ischemic cardiovascular 55 achieved CCyR 55 Apidra ® 55 mm Stent 55 moderate hepatic impairment 55 poor metabolizers 55 defibrillator CRT D 55 statin monotherapy 55 Chronic HCV 55 Index CDAI 55 ACTOplus met 55 iodixanol 55 x ULN 55 CrCl 55 postoperative morbidity 55 VTE 55 fosamprenavir 55 adenoma recurrence 55 coronary stenosis 55 overt nephropathy 55 bone marrow reticulin deposition 55 venous blood clots 55 revascularization procedures 55 metoprolol tartrate 55 MACCE 55 -#.# mg dL [002] 55 angiographic outcomes 55 postoperative AF 55 endophthalmitis 55 hemoglobin A1c HbA1c 55 serum urate 55 cerebral vasospasm 55 baseline HbA1c 55 recurrent wheezing 55 LEXIVA r 55 glycoprotein IIb IIIa inhibitors 55 adefovir treated 55 nonvertebral fracture 55 rebleeding 55 desvenlafaxine succinate 55 perindopril 55 mCi kg 55 DYSPORT 55 terbutaline 55 atazanavir ritonavir 55 thromboembolic disease 55 placebo dexamethasone 55 Ejection Fraction 55 Zovirax acyclovir 55 ABCB1 55 receiving VICTRELIS 55 Scale EDSS score 55 patients undergoing percutaneous 55 bezafibrate 55 tissue plasminogen activator tPA 55 log# IU mL 55 Hydrochloride Injection 55 alpha blocker 55 lipid lowering drugs 55 recurrent myocardial infarction 55 thrombolytics 55 mg kg dose 55 atheroma volume 55 pulmonary embolism PE 55 Tenormin 55 thiazide diuretics 55 adrenal insufficiency 55 tumor lysis syndrome 55 XIENCE V demonstrated 55 deferoxamine 55 diabetic gastroparesis 55 repeat revascularization 55 plus COPEGUS 55 serum triglyceride levels 55 macroalbuminuria 55 bivalirudin monotherapy 55 sirolimus eluting stent 55 plus gemcitabine 55 annualized relapse 55 verapamil 55 carotid intima media 55 venous thromboembolism 55 Severe hypoglycemia 55 antithrombotic therapy 55 ranolazine 55 ABC/3TC 55 thrombocytopenic 55 placebo p = 55 Mometasone 55 oxycodone IR 55 Coronary Artery Bypass Graft 55 adriamycin 55 p = #.# [003] 55 Aortic Stenosis 55 sirolimus eluting 55 intracerebral hemorrhage ICH 55 tipranavir r 55 sunitinib Sutent 54 ACR# response 54 DAPT 54 CDAI score 54 Stent thrombosis 54 cervical intraepithelial neoplasia 54 postmenopausal osteoporotic women 54 intima media thickness 54 prespecified 54 prednisone prednisolone plus 54 HBeAg negative 54 nondiabetic patients 54 oral antidiabetes 54 % CI #.#-#.# [003] 54 rFSH 54 diuretic chlorthalidone 54 AA Amyloidosis 54 Precose 54 hypoglycemic events 54 achieved PASI 54 glycoprotein IIb IIIa inhibitor 54 OMNARIS 54 atazanavir Reyataz 54 intraventricular hemorrhage 54 antiplatelet therapy 54 unstable angina pectoris 54 Benzoyl Peroxide 54 angiotensin converting enzyme 54 postoperative mortality 54 #mg capsules [001] 54 fibrinolysis 54 -#.# ± [002] 54 UCB Keppra 54 endarterectomy 54 Betaferon ® 54 vertebral fracture 54 rosuvastatin 54 peginterferon alfa 2b 54 hypercalcemia 54 PREZISTA ritonavir 54 renal dysfunction 54 Keppra XR 54 alanine aminotransferase 54 Atypical Hemolytic Uremic Syndrome 54 Sustained Virological Response 54 hypotension 54 serum creatinine levels 54 Bronchopulmonary Dysplasia 54 Taxus Stent 54 aspartate aminotransferase 54 corticosteroid therapy 54 Postoperative complications 54 fibrinolytic 54 ritonavir boosted 54 sustained ventricular tachycardia 54 bronchial hyperresponsiveness 54 RISPERDAL ® 54 anthracycline taxane 54 Torsades de Pointes 54 draining enterocutaneous 54 0mg 54 ONGLYZA 54 Atherosclerotic 54 dapagliflozin plus 54 teriflunomide 54 rt PA 54 ALT flares 54 HCTZ 54 hypophosphatemia 54 lipid parameters 54 receiving PEGINTRON 54 histologic subtype 54 mL/min/#.# m2 54 Zyban bupropion 54 severe asthma exacerbations 54 mg ustekinumab 54 anagrelide 54 myocardial infarction 54 induce orthostatic hypotension 54 #.#mmol L [001] 54 peripheral sensory neuropathy 54 prostate TURP 54 mU liter 54 mcg kg REBETOL 54 creatinine clearance 54 beta blockers ACE inhibitors 54 neutropenic sepsis 54 extrapyramidal symptoms 54 HSCT 54 HDL Cholesterol 54 angina pectoris 54 mixed hyperlipidemia 54 urate lowering therapy 54 sulphonylurea 54 CDAI 54 % Confidence Interval 54 anastomotic leak 54 paroxysmal AF 54 hematologic toxicity 54 pioglitazone 54 Febrile neutropenia 54 REYATAZ r arm 54 serum phosphate 54 Acute Coronary Syndromes ACS 54 variceal 54 recombinant tissue plasminogen 54 inhaled budesonide 54 Exacerbations 54 ribavirin RBV 54 oral hypoglycemic agents 54 prospectively stratified 54 thrombotic complications 54 angiotensin receptor blockers ARBs 54 ACE inhibitor benazepril 54 oral levofloxacin 54 administering XIFAXAN 54 calculated creatinine clearance 54 VSL # 54 DES implantation 54 â ‰ ¥ 54 microg 54 HBeAg 54 rimonabant #mg 54 distal embolization thrombus formation 54 infarct size 54 angiotensin converting enzyme ACE 53 neutrophil counts 53 Topiramate 53 beta2 agonist 53 coronary revascularization 53 ischemic cardiomyopathy 53 cerebrovascular accident 53 lowest tertile 53 LNG IUS 53 variceal hemorrhage 53 lipid lowering medications 53 mean baseline A1C 53 ropivacaine 53 % CI #.#-#.# [007] 53 anemia hemoglobin 53 budesonide formoterol 53 IRLS score 53 HAM D# scores 53 Drug eluting stent 53 Thromboembolism 53 Myocardial infarction 53 inhaled fluticasone 53 SCIg 53 8mg/kg 53 antibody titer 53 sternal wound infection 53 renal insufficiency 53 SVR# 53 Secondary endpoints included 53 streptokinase 53 doxorubicin docetaxel 53 leiomyomas 53 myocardial reperfusion 53 Amnesteem 53 elevated LDH 53 EDSS score 53 #.#mmHg 53 adefovir 53 CMV infection 53 achieved statistical significance 53 hemorrhagic complications 53 Kaplan Meier analysis 53 MADRS score 53 mso footer margin 53 triglyceride TG 53 KRAS mutations occur 53 mechanically ventilated patients 53 neuropathy sensory 53 bosentan 53 Scale EDSS 53 confirmed CCyR 53 LVSD 53 Spiriva ® 53 interleukin IL -6 53 PLX STROKE targeting 53 Rating Scale MADRS 53 colectomy 53 serologically active patients 53 postoperative atrial fibrillation 53 perioperatively 53 TDF FTC 53 Cholesterol lowering 53 Unstable angina 53 INVIRASE 53 confidence interval CI 53 Brimonidine 53 hyperglycaemia 53 hematological parameters 53 elevated triglyceride levels 53 sustained virological response 53 thrombolytic therapy 53 ruboxistaurin 53 steroid dexamethasone 53 Unified Parkinson Disease 53 plasminogen activator inhibitor 53 Oral corticosteroids 53 antihypertensive medication 53 advanced adenoma 53 primary percutaneous coronary 53 paclitaxel eluting stents 53 COPD exacerbation 53 Anticonvulsants 53 solifenacin 53 NYHA Class III 53 intraoperative complications 53 Lupuzor ™ 53 placebo p 53 Q2W 53 parathyroidectomy 53 systemic hypotension 53 glomerular filtration rate 53 hyperphenylalaninemia HPA due 53 mg q#h 53 dyslipidaemia 53 Psoriasis Area 53 albumin excretion rate 53 serum leptin 53 ALT normalization 53 coronary intervention 53 dose atorvastatin 53 androgen deprivation 53 Myocardial Infarction Study 53 μmol L 53 postprandial glycemia 53 cerebral infarction 53 C Reactive Protein 53 sulfonylurea 53 beta blocker therapy 53 FLEXERIL 53 Glucophage metformin 53 mmol l 53 IV bolus 53 ST elevation myocardial 53 microvascular complications 53 transaminase elevations 53 antibiotic Avelox 53 Zaditor 53 invasive fungal infection 53 Primary endpoints 53 hip BMD 53 hours postdose 53 esomeprazole 53 anterior uveitis 53 VaD 53 coronary revascularisation 53 antihypertensive agents 53 fraction LVEF 53 noncardiovascular 53 ribavirin therapy 53 QD dosing 53 hemodynamically significant 53 unstable angina UA 53 elevated IOP 53 Antihistamine 53 mmHg diastolic 53 HPA axis suppression 53 chemoradiotherapy 53 stent thromboses 53 CI -#.# 53 sitosterol 53 Hepatitis C Genotype 53 perioperative complications 53 HOMA IR 53 CI #.#-#.# [001] 53 active comparator 53 sirolimus eluting stents 53 Prehypertension 53 HbA1C 53 H2RAs 53 variceal bleeding 53 log# reduction 53 lamivudine monotherapy 53 Amikacin 53 malignancy HCM 53 glitazones 53 deoxy 53 postoperative infections 52 noninferiority 52 STEMI ST 52 peginterferon 52 leukotriene pathway 52 atherothrombotic disease 52 coronary revascularization procedures 52 sinus bradycardia 52 pT3 52 death dissection perforation 52 triiodothyronine 52 mEq 52 aplastic anemia AA 52 proximal DVT 52 mild renal insufficiency 52 Montgomery Asberg Depression 52 glargine 52 VTE prophylaxis 52 CYPHER ® Stent 52 prospectively defined 52 mg dose 52 ExTRACT TIMI 52 carvedilol 52 Astepro 52 Sumatriptan Succinate 52 Carotid Revascularization Endarterectomy vs. 52 secondary endpoint 52 recurrent atrial fibrillation 52 μg L 52 mediastinitis 52 antihypertensive medications 52 ventricular fibrillation VF 52 epoetin beta 52 MCyR 52 hypercalciuria 52 thrombus aspiration 52 prolonged QT interval 52 Oral Rinse 52 Non inferiority 52 metastatic renal cell carcinoma 52 carotid artery stenting CAS 52 #mg QD [002] 52 DETROL LA 52 target vessel revascularization 52 fasting triglycerides 52 mcg kg 52 periprocedural MI 52 Free Survival PFS 52 #mg capsules [002] 52 urinary oxalate 52 HbA1c levels 52 Acute Coronary Syndrome 52 Pfizer Norvasc 52 #μg [001] 52 pravastatin therapy 52 QT prolongation 52 uM 52 left ventricular dysfunction 52 eosinophil count 52 hepatic impairment 52 dose colchicine 52 chronic thromboembolic pulmonary 52 virologic failure 52 Meridia sibutramine 52 Ischemic stroke 52 intracerebral hemorrhage 52 cystoid macular edema 52 injectable emulsion 52 nonsignificant difference 52 hyperkalemia 52 atrophic gastritis 52 Glucose Metabolism 52 ug ml 52 STN stimulation 52 DAS# [002] 52 Azactam 52 Desonate 52 #mg/dl 52 HbA1C levels 52 #mg/kg [002] 52 diameter stenosis 52 CVD mortality 52 g dl 52 platelet reactivity 52 OADs 52 -#.# mmol L 52 IV tPA 52 dronedarone 52 HbA 1c 52 TNF antagonist 52 stable angina 52 Response Evaluation Criteria 52 placebo PBO 52 Hydrochloride 52 carotid stenosis 52 antibody titers 52 glyburide 52 pyridostigmine 52 simvastatin ezetimibe 52 apo B 52 hypogonadal men 52 blood Phe 52 UACR 52 pneumonectomy 52 Pramlintide 52 Target Lesion Revascularization TLR 52 postoperative bleeding 52 experienced virologic failure 52 severe hypoglycemic 52 ORTHO TRI CYCLEN LO 52 TAVR 52 neonatal morbidity 52 serum phosphate levels 52 bone marrow reticulin 52 #OC# 52 myocardial infarctions MIs 52 sternal wound infections 52 tiotropium 52 microalbuminuria 52 clopidogrel 52 Interferon beta 52 IMS MAT 52 thienopyridine 52 LDL Cholesterol 52 CABG coronary artery 52 -#.# log# copies mL 52 macrovascular disease 52 methotrexate monotherapy 52 HBV infections 52 EDARBI 52 haemorrhagic strokes 52 infective endocarditis 52 NIHSS score 52 onset diabetes mellitus 52 dose cohort 52 cytopenias 52 gestational hypertension 52 Myocardial Infarction 52 serum homocysteine 52 Expanded Disability Status 52 anticoagulation 52 colorectal liver metastases 52 MADIT II 52 dobutamine 52 CCyR 52 abdominal adiposity 52 left ventricular systolic 52 advanced adenomas 52 endoscopic remission 52 Varespladib 52 LVEF 52 NIH CPSI 52 placebo fluoxetine 52 plasma triglycerides 52 paricalcitol 52 liver histology 52 virologic breakthrough 52 Topamax topiramate 51 mL sec 51 Erythema 51 HES CEL 51 hyperparathyroidism 51 creatinine ratio 51 reperfusion injury 51 Kaplan Meier estimates 51 homocysteine concentrations 51 lymphocyte count 51 drug eluting stent implantation 51 agents ESAs 51 Prostate Cancer Recurrence 51 laboratory abnormalities 51 ketorolac 51 cardiac dysfunction 51 intramuscularly 51 NCEP ATP III 51 hypoglycemic episodes 51 fibrinolytic therapy 51 NYHA functional class